{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:32:59Z","timestamp":1790695979262,"version":"4.1.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T00:00:00Z","timestamp":1447200000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00432-015-2064-5","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T11:08:25Z","timestamp":1447240105000},"page":"1659-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer"],"prefix":"10.1007","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-9261","authenticated-orcid":false,"given":"Dmitri","family":"Pchejetski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albandri","family":"Alfraidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Alshaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aun","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Monzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"2064_CR1","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1017\/S1462399408000744","volume":"10","author":"AM Abukhdeir","year":"2008","unstructured":"Abukhdeir AM, Park BH (2008) P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10:e19","journal-title":"Expert Rev Mol Med"},{"issue":"17","key":"2064_CR2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039\u20132045","journal-title":"J Clin Oncol"},{"issue":"28","key":"2064_CR3","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2006.06.7140","volume":"24","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Brady MF (2006) Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 24(28):4531\u20134533","journal-title":"J Clin Oncol"},{"key":"2064_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2407-9-111","volume":"9","author":"V Auner","year":"2009","unstructured":"Auner V, Kriegshauser G, Tong D, Horvat R, Reinthaller A, Mustea A, Zeillinger R (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9:111","journal-title":"BMC Cancer"},{"issue":"6","key":"2064_CR5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9(6):415\u2013428","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2064_CR6","first-page":"3355","volume":"30","author":"DO Bauerschlag","year":"2010","unstructured":"Bauerschlag DO, Schem C, Tiwari S, Egberts JH, Weigel MT, Kalthoff H, Jonat W, Maass N, Meinhold-Heerlein I (2010) Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Res 30(9):3355\u20133360","journal-title":"Anticancer Res"},{"issue":"2","key":"2064_CR7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)00300-3","volume":"70","author":"JL Benedet","year":"2000","unstructured":"Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70(2):209\u2013262","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"2064_CR8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.breast.2009.09.005","volume":"18","author":"NS Bese","year":"2009","unstructured":"Bese NS, Iribas A, Dirican A, Oksuz D, Atkovar G, Ober A (2009) Ovarian ablation by radiation therapy: Is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients? Breast 18(5):304\u2013308","journal-title":"Breast"},{"issue":"9","key":"2064_CR9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769\u2013784","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2064_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/bjc.1989.320","volume":"60","author":"M Booth","year":"1989","unstructured":"Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case\u2013control study. Br J Cancer 60(4):592\u2013598","journal-title":"Br J Cancer"},{"issue":"6","key":"2064_CR11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ijc.1422","volume":"93","author":"C Bosetti","year":"2001","unstructured":"Bosetti C, Negri E, Franceschi S, Pelucchi C, Talamini R, Montella M, Conti E, La Vecchia C (2001) Diet and ovarian cancer risk: a case\u2013control study in Italy. Int J Cancer 93(6):911\u2013915","journal-title":"Int J Cancer"},{"issue":"11","key":"2064_CR12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"DD Bowtell","year":"2010","unstructured":"Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11):803\u2013808","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2064_CR13","first-page":"399","volume":"12","author":"J Boyd","year":"1998","unstructured":"Boyd J (1998) Molecular genetics of hereditary ovarian cancer. Oncology 12(3):399\u2013406 ; discussion 409\u2013310, 413","journal-title":"Oncology"},{"issue":"33","key":"2064_CR14","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(33):5165\u20135171","journal-title":"J Clin Oncol"},{"issue":"26","key":"2064_CR15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473\u20132483","journal-title":"N Engl J Med"},{"issue":"11","key":"2064_CR16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1358\/dot.2009.45.11.1437052","volume":"45","author":"C Campas-Moya","year":"2009","unstructured":"Campas-Moya C (2009) Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45(11):787\u2013795","journal-title":"Drugs Today"},{"issue":"24","key":"2064_CR17","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351(24):2519\u20132529","journal-title":"N Engl J Med"},{"issue":"Suppl B","key":"2064_CR18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.placenta.2008.08.007","volume":"29","author":"I Cetin","year":"2008","unstructured":"Cetin I, Cozzi V, Antonazzo P (2008) Infertility as a cancer risk factor\u2014a review. Placenta 29(Suppl B):169\u2013177","journal-title":"Placenta"},{"issue":"19","key":"2064_CR19","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1073\/pnas.1934713100","volume":"100","author":"HL Cheng","year":"2003","unstructured":"Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100(19):10794\u201310799","journal-title":"Proc Natl Acad Sci USA"},{"key":"2064_CR20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho KR, Shih Ie M (2009) Ovarian cancer. Annu Rev Pathol 4:287\u2013313","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"2064_CR21","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","volume":"92","author":"JH Choi","year":"2001","unstructured":"Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92(12):1300\u20131304","journal-title":"Jpn J Cancer Res"},{"issue":"12","key":"2064_CR22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(11)70244-3","volume":"12","author":"RL Coleman","year":"2011","unstructured":"Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, Schmeler KM, Iyer RB, Garcia ME, Miller DL, Jackson EF, Ng CS, Kundra V, Jaffe R, Sood AK (2011) Phase 1\u20132 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12(12):1109\u20131117","journal-title":"Lancet Oncol"},{"issue":"5","key":"2064_CR23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3892\/ijo.2014.2334","volume":"44","author":"V Conteduca","year":"2014","unstructured":"Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D, De Giorgi U (2014) The emerging role of anti-angiogenic therapy in ovarian cancer (Review). Int J Oncol 44(5):1417\u20131424","journal-title":"Int J Oncol"},{"issue":"3","key":"2064_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/07357907.2013.876646","volume":"32","author":"L Dai","year":"2014","unstructured":"Dai L, Xia P, Di W (2014) Sphingosine 1-phosphate: A potential molecular target for ovarian cancer therapy? Cancer Invest 32(3):71\u201380","journal-title":"Cancer Invest"},{"issue":"2","key":"2064_CR25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0306-3356(21)00568-9","volume":"10","author":"AJ Dembo","year":"1983","unstructured":"Dembo AJ (1983) Radiation therapy in the management of ovarian cancer. Clin Obstet Gynaecol 10(2):261\u2013278","journal-title":"Clin Obstet Gynaecol"},{"key":"2064_CR01","doi-asserted-by":"crossref","unstructured":"D'Andrea AD, Grompe M (2003) The Fanconi anaemia\/BRCA pathway. Nat Rev Cancer 3(1):23\u201334","DOI":"10.1038\/nrc970"},{"issue":"1","key":"2064_CR26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nm1173","volume":"11","author":"DM Dinulescu","year":"2005","unstructured":"Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63\u201370","journal-title":"Nat Med"},{"key":"2064_CR27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.45.120403.095825","volume":"45","author":"DC Drummond","year":"2005","unstructured":"Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495\u2013528","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1 Suppl 5","key":"2064_CR28","first-page":"S5-2","volume":"24","author":"CJ Dunton","year":"1997","unstructured":"Dunton CJ (1997) New options for the treatment of advanced ovarian cancer. Semin Oncol 24(1 Suppl 5):S5-2\u2013S5-11","journal-title":"Semin Oncol"},{"issue":"3","key":"2064_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0167-8140(99)00144-9","volume":"53","author":"N Einhorn","year":"1999","unstructured":"Einhorn N, Lundell M, Nilsson B, Ragnarsson-Olding B, Sjovall K (1999) Is there place for radiotherapy in the treatment of advanced ovarian cancer? Radiother Oncol 53(3):213\u2013218","journal-title":"Radiother Oncol"},{"issue":"5\u20136","key":"2064_CR30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/02841860310014426","volume":"42","author":"N Einhorn","year":"2003","unstructured":"Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin-Stahl E (2003) A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol 42(5\u20136):562\u2013566","journal-title":"Acta Oncol"},{"issue":"7716","key":"2064_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","volume":"2","author":"MF Fathalla","year":"1971","unstructured":"Fathalla MF (1971) Incessant ovulation\u2014A factor in ovarian neoplasia? Lancet 2(7716):163","journal-title":"Lancet"},{"issue":"6749","key":"2064_CR32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"MS Finnin","year":"1999","unstructured":"Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749):188\u2013193","journal-title":"Nature"},{"issue":"1","key":"2064_CR33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(01)00429-4","volume":"9","author":"W Fischle","year":"2002","unstructured":"Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E (2002) Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT\/N-CoR. Mol Cell 9(1):45\u201357","journal-title":"Mol Cell"},{"issue":"3","key":"2064_CR34","first-page":"305","volume":"25","author":"ML Friedlander","year":"1998","unstructured":"Friedlander ML (1998) Prognostic factors in ovarian cancer. Semin Oncol 25(3):305\u2013314","journal-title":"Semin Oncol"},{"issue":"3","key":"2064_CR35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ygyno.2007.02.015","volume":"105","author":"M Fung-Kee-Fung","year":"2007","unstructured":"Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A (2007) Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol 105(3):747\u2013756","journal-title":"Gynecol Oncol"},{"issue":"17","key":"2064_CR36","first-page":"4916","volume":"62","author":"R Furumai","year":"2002","unstructured":"Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62(17):4916\u20134921","journal-title":"Cancer Res"},{"issue":"8","key":"2064_CR37","doi-asserted-by":"crossref","first-page":"15885","DOI":"10.3390\/ijms140815885","volume":"14","author":"NG Gavalas","year":"2013","unstructured":"Gavalas NG, Liontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, Dimopoulos MA, Bamias A (2013) Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci 14(8):15885\u201315909","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2064_CR38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.gde.2010.03.001","volume":"20","author":"SA Gayther","year":"2010","unstructured":"Gayther SA, Pharoah PD (2010) The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 20(3):231\u2013238","journal-title":"Curr Opin Genet Dev"},{"key":"2064_CR39","doi-asserted-by":"crossref","unstructured":"Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, DiCioccio R, McGuire V, Webb PM, Beesley J, Green AC, Whiteman DC, Australian Ovarian Cancer Study G, Goodman MT, Lurie G, Carney ME, Modugno F, Ness RB, Edwards RP, Moysich KB, Goode EL, Couch FJ, Cunningham JM, Sellers TA, Wu AH, Pike MC, Iversen ES, Marks JR, Garcia-Closas M, Brinton L, Lissowska J, Peplonska B, Easton DF, Jacobs I, Ponder BA, Schildkraut J, Pearce CL, Chenevix-Trench G, Berchuck A, Pharoah PD, Ovarian Cancer Association C (2007). Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 67(7): 3027\u20133035","DOI":"10.1158\/0008-5472.CAN-06-3261"},{"issue":"1","key":"2064_CR40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0197-103","volume":"15","author":"SA Gayther","year":"1997","unstructured":"Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15(1):103\u2013105","journal-title":"Nat Genet"},{"issue":"2","key":"2064_CR41","first-page":"151","volume":"2","author":"KB Glaser","year":"2003","unstructured":"Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2(2):151\u2013163","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2064_CR42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.22371","volume":"109","author":"BA Goff","year":"2007","unstructured":"Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109(2):221\u2013227","journal-title":"Cancer"},{"issue":"1","key":"2064_CR43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2010.03.012","volume":"118","author":"C Gomez-Raposo","year":"2010","unstructured":"Gomez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A (2010) Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 118(1):88\u201392","journal-title":"Gynecol Oncol"},{"issue":"22","key":"2064_CR44","first-page":"5195","volume":"55","author":"JR Graff","year":"1995","unstructured":"Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55(22):5195\u20135199","journal-title":"Cancer Res"},{"issue":"6","key":"2064_CR45","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/MCB.25.6.2273-2287.2005","volume":"25","author":"S Gregoire","year":"2005","unstructured":"Gregoire S, Yang XJ (2005) Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors. Mol Cell Biol 25(6):2273\u20132287","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2064_CR46","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1073\/pnas.96.9.4868","volume":"96","author":"CM Grozinger","year":"1999","unstructured":"Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 96(9):4868\u20134873","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5945","key":"2064_CR47","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","volume":"325","author":"NC Hait","year":"2009","unstructured":"Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325(5945):1254\u20131257","journal-title":"Science"},{"key":"2064_CR48","doi-asserted-by":"crossref","unstructured":"Havrilesky L, Darcy k\u00a0M, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A, S. Gynecologic Oncology Group (2003) Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21(20): 3814\u2013382","DOI":"10.1200\/JCO.2003.11.052"},{"issue":"6","key":"2064_CR49","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/ijc.25151","volume":"127","author":"A Hayashi","year":"2010","unstructured":"Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T (2010) Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 127(6):1332\u20131346","journal-title":"Int J Cancer"},{"issue":"11","key":"2064_CR50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/ncponc0637","volume":"3","author":"TJ Herzog","year":"2006","unstructured":"Herzog TJ, Pothuri B (2006) Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol 3(11):604\u2013611","journal-title":"Nat Clin Pract Oncol"},{"issue":"2","key":"2064_CR51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1124\/jpet.103.055541","volume":"307","author":"E Hu","year":"2003","unstructured":"Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M (2003) Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307(2):720\u2013728","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2064_CR52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","volume":"12","author":"BH Huang","year":"2005","unstructured":"Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12(4):395\u2013404","journal-title":"Cell Death Differ"},{"issue":"9","key":"2064_CR53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0b013e3283300a0f","volume":"20","author":"JJ Hwang","year":"2009","unstructured":"Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS (2009) A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. Anticancer Drugs 20(9):815\u2013821","journal-title":"Anticancer Drugs"},{"issue":"4","key":"2064_CR54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","volume":"30","author":"BY Karlan","year":"2012","unstructured":"Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, Covens A, Nagarkar RV, Davy M, Leath CA 3rd, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362\u2013371","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"2064_CR55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0027-5107(01)00141-5","volume":"478","author":"M Kartalou","year":"2001","unstructured":"Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478(1\u20132):23\u201343","journal-title":"Mutat Res"},{"issue":"5","key":"2064_CR56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4161\/cbt.6.5.4007","volume":"6","author":"D Khabele","year":"2007","unstructured":"Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM (2007) Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 6(5):795\u2013801","journal-title":"Cancer Biol Ther"},{"issue":"21","key":"2064_CR57","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63(21):7291\u20137300","journal-title":"Cancer Res"},{"issue":"3","key":"2064_CR58","first-page":"1048","volume":"44","author":"TL Klug","year":"1984","unstructured":"Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr (1984) Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44(3):1048\u20131053","journal-title":"Cancer Res"},{"issue":"2","key":"2064_CR59","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ygyno.2006.05.007","volume":"103","author":"IK Kolasa","year":"2006","unstructured":"Kolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM, Konopka B, Kupryjanczyk J (2006) PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 103(2):692\u2013697","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2064_CR60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2011.04.046","volume":"122","author":"K Kudoh","year":"2011","unstructured":"Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, Watanabe A, Kato M, Goto T, Kikuchi Y (2011) Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 122(2):233\u2013237","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2064_CR61","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2004.10.037","volume":"96","author":"AW Kurian","year":"2005","unstructured":"Kurian AW, Balise RR, McGuire V, Whittemore AS (2005) Histologic types of epithelial ovarian cancer: Have they different risk factors? Gynecol Oncol 96(2):520\u2013530","journal-title":"Gynecol Oncol"},{"issue":"32","key":"2064_CR62","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459\u20135468","journal-title":"J Clin Oncol"},{"issue":"2","key":"2064_CR63","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2004.01.043","volume":"93","author":"MM Leitao","year":"2004","unstructured":"Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J (2004) Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 93(2):301\u2013306","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2064_CR64","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1349-7006.2008.00793.x","volume":"99","author":"CT Lin","year":"2008","unstructured":"Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH (2008) Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 99(6):1218\u20131226","journal-title":"Cancer Sci"},{"issue":"2","key":"2064_CR65","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ygyno.2009.03.015","volume":"114","author":"KA Lowe","year":"2009","unstructured":"Lowe KA, Andersen MR, Urban N, Paley P, Dresher CW, Goff BA (2009) The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. Gynecol Oncol 114(2):225\u2013230","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2064_CR66","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/dvdy.21626","volume":"237","author":"JL MacDonald","year":"2008","unstructured":"MacDonald JL, Roskams AJ (2008) Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev Dyn 237(8):2256\u20132267","journal-title":"Dev Dyn"},{"issue":"9","key":"2064_CR67","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/jm049002a","volume":"48","author":"A Mai","year":"2005","unstructured":"Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 48(9):3344\u20133353","journal-title":"J Med Chem"},{"issue":"1","key":"2064_CR68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.7810","volume":"5","author":"CS Marcus","year":"2014","unstructured":"Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP (2014) Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer 5(1):25\u201330","journal-title":"J Cancer"},{"issue":"3","key":"2064_CR69","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1040-8428(01)00097-X","volume":"38","author":"M Markman","year":"2001","unstructured":"Markman M (2001) Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. Crit Rev Oncol Hematol 38(3):171\u2013175","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2064_CR70","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1(3):194\u2013202","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2064_CR71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1098-2388(200007\/08)19:1<11::AID-SSU3>3.0.CO;2-3","volume":"19","author":"DE Marsden","year":"2000","unstructured":"Marsden DE, Friedlander M, Hacker NF (2000) Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 19(1):11\u201319","journal-title":"Semin Surg Oncol"},{"issue":"1","key":"2064_CR72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","volume":"29","author":"D Matei","year":"2011","unstructured":"Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 29(1):69\u201375","journal-title":"J Clin Oncol"},{"issue":"16","key":"2064_CR73","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","volume":"117","author":"KF McGonigle","year":"2011","unstructured":"McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, Goff BA, Gray HJ, Malpass TW (2011) Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 117(16):3731\u20133740","journal-title":"Cancer"},{"issue":"9","key":"2064_CR74","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1054\/bjoc.2000.1174","volume":"82","author":"T Meyer","year":"2000","unstructured":"Meyer T, Rustin GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82(9):1535\u20131538","journal-title":"Br J Cancer"},{"issue":"2","key":"2064_CR75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","volume":"109","author":"SC Modesitt","year":"2008","unstructured":"Modesitt SC, Sill M, Hoffman JS, Bender DP, Gynecologic Oncology G (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109(2):182\u2013186","journal-title":"Gynecol Oncol"},{"key":"2064_CR76","first-page":"CD005343","volume":"4","author":"J Morrison","year":"2007","unstructured":"Morrison J, Swanton A, Collins S, Kehoe S (2007) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 4:CD005343","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2064_CR77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/onc.2008.371","volume":"28","author":"D Mottet","year":"2009","unstructured":"Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin E, Castronovo V (2009) HDAC4 represses p21(WAF1\/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28(2):243\u2013256","journal-title":"Oncogene"},{"issue":"5","key":"2064_CR78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5(5):355\u2013366","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2064_CR79","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tips.2005.01.002","volume":"26","author":"M Ohmichi","year":"2005","unstructured":"Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y (2005) Mechanisms of platinum drug resistance. Trends Pharmacol Sci 26(3):113\u2013116","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"2064_CR80","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1349-7006.2007.00669.x","volume":"99","author":"K Ozaki","year":"2008","unstructured":"Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M (2008) Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99(2):376\u2013384","journal-title":"Cancer Sci"},{"issue":"17","key":"2064_CR81","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194\u20133200","journal-title":"J Clin Oncol"},{"issue":"2","key":"2064_CR82","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1525-1438.2007.01000.x","volume":"18","author":"JE Palmer","year":"2008","unstructured":"Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP (2008) P53 and bcl-2 assessment in serous ovarian carcinoma. Int J Gynecol Cancer 18(2):241\u2013248","journal-title":"Int J Gynecol Cancer"},{"key":"2064_CR83","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","volume":"472","author":"J Permuth-Wey","year":"2009","unstructured":"Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472:413\u2013437","journal-title":"Methods Mol Biol"},{"issue":"26","key":"2064_CR84","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496","journal-title":"N Engl J Med"},{"issue":"9","key":"2064_CR85","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1023\/A:1012259625746","volume":"12","author":"MJ Piccart","year":"2001","unstructured":"Piccart MJ, Lamb H, Vermorken JB (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12(9):1195\u20131203","journal-title":"Ann Oncol"},{"issue":"3","key":"2064_CR86","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ygyno.2003.11.022","volume":"92","author":"JM Piek","year":"2004","unstructured":"Piek JM, Dorsman JC, Shvarts A, Ansink AC, Massuger LF, Scholten P, van Diest PJ, Dijkstra JC, Weegenaar J, Kenemans P, Verheijen RH (2004) Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. Gynecol Oncol 92(3):819\u2013826","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2064_CR87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1083\/jcb.104.2.289","volume":"104","author":"G Piperno","year":"1987","unstructured":"Piperno G, LeDizet M, Chang XJ (1987) Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 104(2):289\u2013302","journal-title":"J Cell Biol"},{"issue":"7","key":"2064_CR88","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/annonc\/mdg299","volume":"14","author":"J Plisiecka-Halasa","year":"2003","unstructured":"Plisiecka-Halasa J, Karpinska G, Szymanska T, Ziolkowska I, Madry R, Timorek A, Debniak J, Ulanska M, Jedryka M, Chudecka-Glaz A, Klimek M, Rembiszewska A, Kraszewska E, Dybowski B, Markowska J, Emerich J, Pluzanska A, Goluda M, Rzepka-Gorska I, Urbanski K, Zielinski J, Stelmachow J, Chrabowska M, Kupryjanczyk J (2003) P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 14(7):1078\u20131085","journal-title":"Ann Oncol"},{"issue":"8","key":"2064_CR89","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.humpath.2005.06.006","volume":"36","author":"J Prat","year":"2005","unstructured":"Prat J, Ribe A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol 36(8):861\u2013870","journal-title":"Hum Pathol"},{"issue":"8","key":"2064_CR90","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","volume":"5","author":"X Qian","year":"2006","unstructured":"Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5(8):2086\u20132095","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2064_CR91","first-page":"15","volume":"4","author":"JA Rauh-Hain","year":"2011","unstructured":"Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB (2011) Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 4(1):15\u201321","journal-title":"Rev Obstet Gynecol"},{"key":"2064_CR92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fonc.2014.00045","volume":"4","author":"JR Ribeiro","year":"2014","unstructured":"Ribeiro JR, Lovasco LA, Vanderhyden BC, Freiman RN (2014) Targeting TBP-associated factors in ovarian cancer. Front Oncol 4:45","journal-title":"Front Oncol"},{"issue":"1","key":"2064_CR93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1055-9965.EPI-06-0755","volume":"16","author":"S Rinaldi","year":"2007","unstructured":"Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A, Oikonomou E, Pera G, Larranaga N, Martinez-Garcia C, Ardanaz E, Quiros JR, Tormo MJ, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Linseisen J, Schulz M, Boeing H, van Gils CH, Bueno-de-Mesquita BH, Pala V, Palli D, Panico S, Tumino R, Vineis P, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC, Lundin E, Agren A, Berglund G, Manjer J, Kumle M, Lund E, Slimani N, Saracci R, Riboli E, Kaaks R (2007) Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 16(1):23\u201329","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"2064_CR94","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/jnci\/90.23.1774","volume":"90","author":"HA Risch","year":"1998","unstructured":"Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774\u20131786","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2064_CR95","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","volume":"96","author":"A Saito","year":"1999","unstructured":"Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96(8):4592\u20134597","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2064_CR96","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","volume":"68","author":"K Sawada","year":"2008","unstructured":"Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E (2008) Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68(7):2329\u20132339","journal-title":"Cancer Res"},{"issue":"14","key":"2064_CR97","first-page":"4041","volume":"62","author":"MJ Scanlan","year":"2002","unstructured":"Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ (2002) Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 62(14):4041\u20134047","journal-title":"Cancer Res"},{"issue":"3","key":"2064_CR98","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/humu.10181","volume":"21","author":"M Schuijer","year":"2003","unstructured":"Schuijer M, Berns EM (2003) TP53 and ovarian cancer. Hum Mutat 21(3):285\u2013291","journal-title":"Hum Mutat"},{"issue":"12","key":"2064_CR99","first-page":"1422","volume":"4","author":"JP Secrist","year":"2003","unstructured":"Secrist JP, Zhou X, Richon VM (2003) HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 4(12):1422\u20131427","journal-title":"Curr Opin Investig Drugs"},{"issue":"13","key":"2064_CR100","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/MCB.00494-07","volume":"27","author":"S Senese","year":"2007","unstructured":"Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S (2007) Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27(13):4784\u20134795","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2064_CR101","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ijc.21240","volume":"117","author":"YV Shebzukhov","year":"2005","unstructured":"Shebzukhov YV, Koroleva EP, Khlgatian SV, Belousov PV, Kuz\u2019mina KE, Radko BV, Longpre F, Lagarkova MA, Kadachigova TS, Gurova OV, Meshcheryakov AA, Lichinitser MR, Knuth A, Jager E, Kuprash DV, Nedospasov SA (2005) Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int J Cancer 117(5):800\u2013806","journal-title":"Int J Cancer"},{"issue":"4","key":"2064_CR102","first-page":"1519","volume":"34","author":"E Smolle","year":"2014","unstructured":"Smolle E, Taucher V, Petru E, Haybaeck J (2014) Targeted treatment of ovarian cancer-the multiple-kinase-inhibitor sorafenib as a potential option. Anticancer Res 34(4):1519\u20131530","journal-title":"Anticancer Res"},{"key":"2064_CR103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-6-183","volume":"6","author":"J Sonnemann","year":"2006","unstructured":"Sonnemann J, Gange J, Pilz S, Stotzer C, Ohlinger R, Belau A, Lorenz G, Beck JF (2006) Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6:183","journal-title":"BMC Cancer"},{"issue":"1","key":"2064_CR104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/IGC.0b013e318234fa3a","volume":"22","author":"B Sorbe","year":"2012","unstructured":"Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshoj R, Lood M, Malmstrom H (2012) Phase II study of docetaxel weekly in combination with carboplatin every 3\u00a0weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer. Int J Gynecol Cancer 22(1):47\u201353","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"2064_CR105","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2011.267","volume":"31","author":"S Spiegel","year":"2012","unstructured":"Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31(5):537\u2013551","journal-title":"Oncogene"},{"issue":"6765","key":"2064_CR106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","volume":"403","author":"BD Strahl","year":"2000","unstructured":"Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403(6765):41\u201345","journal-title":"Nature"},{"issue":"16","key":"2064_CR107","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199704173361602","volume":"336","author":"JF Stratton","year":"1997","unstructured":"Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA (1997) Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336(16):1125\u20131130","journal-title":"N Engl J Med"},{"issue":"5","key":"2064_CR108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1101\/gad.12.5.599","volume":"12","author":"K Struhl","year":"1998","unstructured":"Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12(5):599\u2013606","journal-title":"Genes Dev"},{"issue":"5","key":"2064_CR109","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965\u2013972","journal-title":"J Clin Oncol"},{"issue":"24","key":"2064_CR110","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.2174\/092986707782023299","volume":"14","author":"N Takai","year":"2007","unstructured":"Takai N, Narahara H (2007) Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14(24):2548\u20132553","journal-title":"Curr Med Chem"},{"issue":"12","key":"2064_CR111","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","volume":"101","author":"N Takai","year":"2004","unstructured":"Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP (2004) Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101(12):2760\u20132770","journal-title":"Cancer"},{"issue":"2","key":"2064_CR112","first-page":"323","volume":"17","author":"N Takai","year":"2006","unstructured":"Takai N, Ueda T, Nishida M, Nasu K, Narahara H (2006) A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med 17(2):323\u2013329","journal-title":"Int J Mol Med"},{"key":"2064_CR113","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/jcb.240590927","volume":"23","author":"G Tortolero-Luna","year":"1995","unstructured":"Tortolero-Luna G, Mitchell MF (1995) The epidemiology of ovarian cancer. J Cell Biochem Suppl 23:200\u2013207","journal-title":"J Cell Biochem Suppl"},{"key":"2064_CR114","doi-asserted-by":"crossref","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study G, Gertig D, DeFazio A, Bowtell DD (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16):5198\u20135208","DOI":"10.1158\/1078-0432.CCR-08-0196"},{"issue":"3","key":"2064_CR115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0305-7372(95)90002-0","volume":"21","author":"MK Tuxen","year":"1995","unstructured":"Tuxen MK, Soletormos G, Dombernowsky P (1995) Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 21(3):215\u2013245","journal-title":"Cancer Treat Rev"},{"issue":"42","key":"2064_CR116","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","volume":"101","author":"A Vannini","year":"2004","unstructured":"Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C, Di Marco S (2004) Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101(42):15064\u201315069","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2064_CR117","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0168-9525(03)00073-8","volume":"19","author":"E Verdin","year":"2003","unstructured":"Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19(5):286\u2013293","journal-title":"Trends Genet"},{"issue":"2","key":"2064_CR118","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.20372","volume":"112","author":"A Villar-Garea","year":"2004","unstructured":"Villar-Garea A, Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112(2):171\u2013178","journal-title":"Int J Cancer"},{"issue":"1","key":"2064_CR119","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","volume":"100","author":"JL Walker","year":"2006","unstructured":"Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100(1):27\u201332","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2064_CR120","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1096\/fj.04-2303fje","volume":"19","author":"D Waltregny","year":"2005","unstructured":"Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A, Castronovo V (2005) Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J 19(8):966\u2013968","journal-title":"FASEB J"},{"issue":"2","key":"2064_CR121","first-page":"157","volume":"25","author":"PH Wang","year":"2004","unstructured":"Wang PH, Chang C (2004) Androgens and ovarian cancers. Eur J Gynaecol Oncol 25(2):157\u2013163","journal-title":"Eur J Gynaecol Oncol"},{"issue":"21","key":"2064_CR122","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","volume":"90","author":"RP Warrell Jr","year":"1998","unstructured":"Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90(21):1621\u20131625","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2064_CR123","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","volume":"65","author":"SR Wedge","year":"2005","unstructured":"Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65(10):4389\u20134400","journal-title":"Cancer Res"},{"issue":"9","key":"2064_CR124","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1593\/neo.08474","volume":"10","author":"W Weichert","year":"2008","unstructured":"Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Kobel M (2008) Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10(9):1021\u20131027","journal-title":"Neoplasia"},{"issue":"4\u20135","key":"2064_CR125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drup.2004.08.002","volume":"7","author":"RP Wernyj","year":"2004","unstructured":"Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles\u2019 heel. Drug Resist Updates 7(4\u20135):227\u2013232","journal-title":"Drug Resist Updates"},{"issue":"19","key":"2064_CR126","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson AJ, Byun DS, Popova N, Murray LB, L\u2019Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281(19):13548\u201313558","journal-title":"J Biol Chem"},{"issue":"5","key":"2064_CR127","doi-asserted-by":"crossref","first-page":"e64954","DOI":"10.1371\/journal.pone.0064954","volume":"8","author":"J Zhang","year":"2013","unstructured":"Zhang J, Chen YL, Ji G, Fang W, Gao Z, Liu Y, Wang J, Ding X, Gao F (2013) Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS ONE 8(5):e64954","journal-title":"PLoS ONE"},{"issue":"5","key":"2064_CR128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","volume":"5","author":"P Zhu","year":"2004","unstructured":"Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5(5):455\u2013463","journal-title":"Cancer Cell"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2064-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-2064-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2064-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:41:11Z","timestamp":1653514871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-2064-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":129,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["2064"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-2064-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]}}}